Skip to main content
. Author manuscript; available in PMC: 2012 Jan 12.
Published in final edited form as: Circulation. 2011 Jun 7;123(22):2591–2601. doi: 10.1161/CIRCULATIONAHA.110.971564

Table 1.

Major Trials of Intravenous and Intra-Arterial Treatment for Acute Ischemic Stroke

Major Stroke Treatment Trials
NINDS
rt-PA18
NINDS rt-PA
Control18
SITS-
MOST15
PROACT II
rtPA19
PROACT-II
Control19
MELT
rtPA20
MELT
Control20
IMS-121 IMS-222 CLOTBUST23 EKOS
124
MERCI
225
MULTI-
MERCI26
Penumbra
Pivotal27
Patients, n 312 312 6483 121 59 57 57 80 81 63 14 141 164 125
Age, y 68 66 68 64 64 67 67 64 67 67 64 67 68 64
Baseline NIHSS 18 18 12 17 17 14 14 18 19 16 18 20 19 18
Revascularization, % 66 18 73 56 60 38 57 48 68 82
Symptomatic ICH, % 1 7 1.7 10.9 2 9 2 6 10 4.8 14 7.8 9.8 11.2
Asymptomatic ICH, % 0.5 24 43 27.7 30.5 16.8
90-d mortality, % 24 21 11 25 27 5.3 3.5 16 16 15 36 43.5 34 32.8
90-d mRS ≤2 28 30 54 40 25 49.1 38.6 43 46 42 43 27.7 36 25

NINDS rt-PA indicates National Institute of Neurological Disorders Tissue Plasminogen Activator for Acute Ischemic Stroke Trial; SITS-MOST, Safe Implementation of Thrombolysis in Stroke-Monitoring Study; PROACT II, Prolyse in Acute Cerebral Thromboembolism trial; rtPA, recombinant tissue-type plasminogen activator; MELT, Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial; IMS, Interventional Management of Stroke; CLOTBUST, randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke; EKOS, EKOS MicroLysUS infusion catheter study; MERCI, Mechanical Embolus Removal in Cerebral Ischemia; NIHSS, National Institutes of Health Stroke Scale; ICH, intracranial hemorrhage; and mRS, modified Rankin Scale.

HHS Vulnerability Disclosure